Recent progress of nanomaterials for diagnosis and treatment of rejection in heart transplantation

TL;DR

This review discusses how nanomaterials are being developed to improve the diagnosis and treatment of heart transplant rejection.

Contribution

The paper highlights recent advances in nanomaterials for targeted drug delivery and imaging in heart transplantation.

Findings

Nanomaterials enhance drug delivery and reduce adverse effects in heart transplant patients.

They serve as molecular probes for early detection of acute rejection through imaging techniques.

Theranostic nanomaterials enable simultaneous diagnosis and treatment of transplant rejection.

Abstract

Transplant rejection and the side effects of immunosuppressive therapy have hindered heart transplantation development. Rejection of a heart transplant can lead to cellular and antibody-mediated immunoinflammatory responses and allograft dysfunction, thereby significantly affecting patients’ survival and prognosis. To address these challenges, many new technologies and materials, including nanomaterials, have been developed for potential applications in the heart transplantation field. Nanomaterials are most commonly used as drug delivery carriers, and the addition of specific ligands can enhance drug utilization, strengthen therapeutic effects, and reduce the occurrence of adverse reactions. In addition, nanomaterials have been developed as targeted molecular probes to support various imaging techniques and to assist in monitoring the infiltration of immune cells (such as T cells and macrophages) into cardiac tissue, thus facilitating the early diagnosis of acute rejection (AR). Continuous advances in nanotechnology have led to the development of “theranostic” and intelligent-response nanomaterials for precise disease diagnosis and simultaneous treatment. Nanomedicine primarily relies on the development of Nanomaterials and nanostructured surfaces, along with the application of nanotechnology, for molecular diagnosis, therapy, monitoring, and disease treatment. In this review, we examine the recent development of nanomaterials for the diagnosis and treatment of AR in heart transplantation, and discuss the challenges and future directions for the clinical translation of nanomaterials in heart transplantation.

Nanomaterials for diagnosis and treatment of rejection in heart transplantation (Guo et al., 2012; Wu W et al., 2013; Braza et al., 2018; Xu et al., 2020). Created in BioRender.Diagram illustrating nano-materials, diagnosis, and treatment in medical applications. Nano-materials include lipid nanobubbles, superparamagnetic iron oxide nanoparticles, radionuclide probes, responsive optical nanoprobes, liposomes, polymer nanoparticles, nanovesicles, and mesoporous silica nanoparticles. Diagnosis methods shown are ultrasound imaging, MRI, PET, and fluorescence imaging for isograft and allograft detection. Treatment section features components like lymph nodes, CD4+ and CD8+ T cells, Treg cells, inflammatory cytokines, and polarization between M1 and M2 macrophages, related to transplant heart care.

Nanomaterials for diagnosis and treatment of rejection in heart transplantation (Guo et al., 2012; Wu W et al., 2013; Braza et al., 2018; Xu et al., 2020). Created in BioRender.

Figures